CIM
VRTX icon

Cambria Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cambria Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Buy
4,593
+838
+22% +$371K 0.11% 189
2026
Q1 		$1.68M Sell
3,755
-830
-18% -$387K 0.09% 172
2025
Q4 		$2.08M Buy
4,585
+404
+10% +$174K 0.12% 174
2025
Q3 		$1.64M Buy
4,181
+271
+7% +$113K 0.1% 173
2025
Q2 		$1.74M Buy
+3,910
New +$1.8M 0.12% 172

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cambria Investment Management's VRTX Position: Q2 2026 in Review

Cambria Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, buying an estimated $371K and bringing the position to 4,593 shares worth $2.28M. The position accounts for 0.11% of the portfolio, ranked #189.

Cambria Investment Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cambria Investment Management held 4,593 shares of Vertex Pharmaceuticals worth $2.28M as of Q2 2026.
  • Cambria Investment Management bought 838 Vertex Pharmaceuticals shares in Q2 2026, an estimated $371K.
  • Vertex Pharmaceuticals made up 0.11% of Cambria Investment Management's portfolio in Q2 2026, its #189 holding.
  • Cambria Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.